

	n	per protocol	minor deviation	major deviation	total not per protocol (minor or major)
Target volume Boost^{a)}	65	38 (58.4%)	23 (35.4%)	4 (6.2%)	27 (41.5%)
Resection cavity^{a)}					
All patients	65	52 (80%)	9 (13.8%)	4 (6.2%)	13 (20.0%)
Pre/post-surgery MRI available	46	38 (82.6%)	7 (15.2%)	1 (2.2%)	8 (17.4%)
No or incomplete MRI data	19	14 (73.8%)	2 (10.5%)	3 (15.7%)	5 (26.3%)
CTV/PTV-margin^{a)}	65	48 (73.8%)	17 (26.2%)	Not defined	17 (26.2%)
Dose uniformity Boost	65	50 (76.9%)	12 (18.5%)	3 (4.6%)	15 (23.1%)
V95% Boost	65	51 (78.5%)	12 (18.5%)	2 (3.1%)	14 (21.5%)
V107% Boost	65	64 (98.5%)	0	1 (1.5%)	1 (1.5%)

Supplementary Table 1 Deviation of target volume delineation and dose uniformity.

^{a)} For target volume delineation, no definition of major and minor deviation are available in the protocol. Quality control was done according definitions in table 1.

MRI – magnetic resonance imaging

CTV – clinical target volume

PTV – planning target volume

V95 - volume of PTV receiving $\geq 95\%$ of the prescribed dose

V107 - volume of PTV receiving $\geq 107\%$ of the prescribed dose

Types of deviation and review criteria in pre-treatment central quality control of tumor bed boost in medulloblastoma – An analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial. Strahlentherapie und Radioonkologie. Dietzsch S et al. Department for Radiation Oncology, University of Leipzig Medical Center, Leipzig, Germany. Email: stefan.dietzsch@medizin.uni-leipzig.de